The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
David E. Gerber
No relevant relationships to disclose
Toby Christopher Campbell
Research Funding - ImClone Systems
Paul Swanson
No relevant relationships to disclose
Ariel Lopez-Chavez
Honoraria - Lilly
Lucas Wong
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Lilly
Afshin Dowlati
No relevant relationships to disclose
Amy Qin
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Jan G. C. E. Cosaert
Employment or Leadership Position - ImClone Systems
Maria Quintos Baggstrom
No relevant relationships to disclose